The need for faster drug launches and increasing post-marketing compliance requirements are the main challenges that pharmaceutical companies confront today. They also grapple with rising R&D costs and the pressure of regulatory compliance while confronting the need to launch their products in established and emerging markets and look for new opportunities to grow. Therefore, their drug development and safety cycles are critical and key partnerships are important for success. This collection has a great combination of articles from industry subject matter experts, customers and research.
- VK Raman, Global Head, TCS' BPO Solutions, sets the tone in his editorial with a perspective on the evolving world of drug development and drug safety.
- Alex Drissen, F Hoffman Roche and Vita Marie Petrik, AstraZeneca, discuss their engagement with TCS for their critical business needs and highlight the benefits they have derived from working with us.
- Dr. Nimita Limaye, VP Biometrics and Medical Writingm, TCS' BPO Solutions, discusses how India is at the forefront of strategic partnerships in clinical data management, biostatistics and medical writing. She also engages Dr. David Clemow of Eli Lilly and Halle Gawrylewski of Janssen in a debate over the core competencies of a medical writer.
- Dr. Neha Achrekar, Consultant, TCS, writes about the importance and the challenges of drug safety for pharmaceutical companies.